OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma
SMMART Program: A multi-omics tumour board with a focus on breast cancer
Clinical validation of a targeted methylation-based multi-cancer early detection test
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC
Highlights from AORTIC Cancer Genomics Conference 2021